Obinutuzumab to induce remission in relapsing PR3-ANCA granulomatosis with polyangiitis
Obinutuzumab for Remission Induction in Patients With Relapsing PR3-ANCA Granulomatosis With Polyangiitis (Wegener's). Phase 2 Prospective, Open-label Study
This trial will try obinutuzumab to bring about clinical and blood-marker remission in adults with relapsing PR3-ANCA granulomatosis with polyangiitis.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Enrollment | 33 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Assistance Publique - Hôpitaux de Paris Academic / other |
| Drugs / interventions | rituximab, obinutuzumab, cyclophosphamide, prednisone |
| Locations | 1 site (Paris) |
| Trial ID | NCT06940661 on ClinicalTrials.gov |
What this trial studies
This is a Phase 2 interventional trial testing obinutuzumab, a humanized type 2 anti-CD20 antibody, to induce clinical and serological remission in patients with relapsing PR3-ANCA granulomatosis with polyangiitis. Eligible adults must have active disease (BVAS ≥ 3) and be PR3-ANCA positive, and treatment is started within a window after initiating or increasing glucocorticoids. The study aims to achieve BVAS=0 and ANCA negativation while monitoring safety and the duration of B-cell depletion. The design builds on prior evidence that B-cell–targeted therapy can induce remission in AAV and seeks deeper or longer remissions than currently available options.
Who should consider this trial
Good fit: Adults (≥18 years) with relapsing PR3-ANCA granulomatosis with polyangiitis who are PR3-ANCA positive, have active disease (BVAS ≥ 3), and are within 21 days of starting or increasing glucocorticoids (≤1 mg/kg/day) and able to consent and attend study visits.
Not a fit: Patients with MPO-positive vasculitis or other non-PR3 vasculitides, those in remission (BVAS < 3), newly diagnosed GPA patients, or those unable to attend the Paris site or provide informed consent are unlikely to benefit from this protocol.
Why it matters
Potential benefit: If successful, obinutuzumab could produce deeper and longer-lasting remissions and lower relapse rates for patients with relapsing PR3-ANCA granulomatosis with polyangiitis.
How similar studies have performed: Rituximab has proven effective for induction and maintenance in AAV and obinutuzumab showed superior B-cell depletion in preclinical work and in some other clinical settings, but its use specifically in relapsing PR3-ANCA granulomatosis with polyangiitis remains largely untested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient aged of 18 years or older, * Patients with relapsing granulomatosis with polyangiitis positive for PR3-ANCA at inclusion according to the ACR/EULAR 2022 classification criteria, and/or the 2012 revised Chapel Hill Consensus Conference definition. * Patients with an active disease defined as a Birmingham Vasculitis Activity Score (BVAS) ≥ 3, * Patients within the first 21 days following initiation/increase of glucocorticoids at a dose ≤1 mg/kg/day (pulses of methylprednisolone before oral glucocorticoid therapy are authorized) * Patient able to give written informed consent prior to participation in the study, - Affiliation with a mode of social security (profit or being entitled). Exclusion Criteria * Patients with MPO-positive AAV, or other vasculitis, defined by the ACR criteria and/or the Chapel Hill Consensus Conference, * Patients with vasculitis in remission of the disease defined as a BVAS \< 3, * Patients with a newly-diagnosis of GPA * Patients treated with rituximab within the last 6 months before inclusion * Patients treated with cyclophosphamide within the last 6 months before inclusion * Patients with severe cardiac failure defined as class IV in New York Heart Association * Subject known to be seropositive for human immunodeficiency virus (HIV), hepatitis B (included history of previous infection) or hepatitis C * Patients with active cancer or recent cancer (\< 5 years), except basocellular carcinoma and prostatic cancer of low activity controlled by hormonal treatment, * Patients with hypersensitivity to a monoclonal antibody or biologic agent, * Patients with hypersensitivity to obinutuzumab or to its excipients * Contra-indications to auxiliary medicinal products (methylprednisolone, paracetamol, prednisone, dexchlorpheniramine) * Patients with other uncontrolled diseases, including drug or alcohol abuse, active infections or antecedents of chronic or recurrent infections, severe psychiatric diseases, that could interfere with participation in the trial according to the protocol, * Patients suspected not to be observant to the proposed treatments, * Pregnant women and lactation. All women of childbearing potential (WOCBP) are required to have a negative pregnancy test (blood or urine) before treatment and must agree to maintain highly effective contraception by practicing abstinence or by using an effective method of birth control from the date of consent through the end of the study, and at least 18 months after stopping obinutuzumab such as combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (Oral, Intravaginal, Transdermal); Progestogen-only hormonal contraception associated with inhibition of ovulation (Oral, Injectable, Implantable); Intrauterine device (IUD); Intrauterine hormone-releasing system (IUS); Bilateral tubal occlusion; Vasectomised partner, * Men who refuse to use effective method of contraception (condom) from the date of consent through the end of the study and at least 18 months after stopping obinutuzumab (unless permanently sterile by bilateral orchidectomy or vasectomy), * Patient participating in another investigational therapeutic study * Protected adults (including individual under legal guardianship by court order or curatorship) or adults deprived of liberty * Patients unable to give written informed consent prior to participation in the study. * Patients with severe liver insufficiency (prothrombin time \<50% and total bilirubin \>50 micrmol/L)) or pulmonary insufficiency requiring nasal oxygen, * Patients with an active infection or a history of chronic or recurrent infections * Vaccination with live virus vaccines in the 4 weeks before study enrolment
Where this trial is running
Paris
- Service de Médecine Interne, Centre de reference "Maladies systémiques et autoimmunes rares, en particulier Vascularites nécrosantes et Sclérodermies systémiques" — Paris, France (Recruiting)
Study contacts
- Study coordinator: Benjamin TERRIER, PhD
- Email: benjamin.terrier@aphp.fr
- Phone: 01 58 41 14 61
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.